Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. 2010

M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany.

Hepatitis B virus reactivation during immunosuppressive therapies can lead to liver failure with very limited treatment options available. We report here on two cases of severe hepatitis B reactivation during chemotherapy including rituximab for B cell lymphoma which were treated with liver or liver-cell transplantation. Liver function was normal and HBV infection was unknown in both patients before chemotherapy was started. Impaired liver function became apparent after 4 and 6 courses of chemotherapy, respectively, and both patients experienced fulminant hepatic failure despite antiviral treatment with lamivudine or entecavir. Patient A underwent liver transplantation after documentation of complete remission of the lymphoma and survived without any evidence for hepatitis B recurrence. Patient B received 4 courses of hepatocyte transplantation but did not survive. These cases underline the importance of anti-HBc screening in patients receiving immunosuppressive treatments in particular when rituximab is given. Pre-emptive antiviral treatments should be administered since delayed antiviral treatment is frequently unable to prevent liver failure.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
April 2010, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi,
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
January 2006, Internal medicine (Tokyo, Japan),
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
December 2019, ACG case reports journal,
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
January 1989, Harefuah,
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
April 2022, Gastroenterologia y hepatologia,
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
December 1994, Journal of hepatology,
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
September 2010, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
August 1992, Digestive diseases and sciences,
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
February 2015, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
M A Stange, and O Tutarel, and S Pischke, and A Schneider, and C P Strassburg, and T Becker, and H Barg-Hock, and M Bastürk, and K Wursthorn, and M Cornberg, and M Ott, and T F Greten, and M P Manns, and H Wedemeyer
January 2015, Pakistan journal of medical sciences,
Copied contents to your clipboard!